


Improving the Precision of Immunotherapies Through Cell Targeting



Johnson & Johnson Innovation is seeking **innovations in cell targeting technology that are highly selective towards immune cells**, with a focus on macrophages and fibroblasts, capable of effectively delivering a drug payload to its target on or within the cell of interest. Technologies that enable intracellular delivery are of greatest interest.

Specific Points of Interest

- Selective targeting of immune cells focusing on macrophages, fibroblasts and also including dendritic cells, myeloid cells, monocytes, T-cells, B-cells, NK cells and neutrophils, including their cell sub-types
- Targeting of receptors, cell surface proteins and their corresponding ligands to enable drug payload internalisation
- Leveraging enzymes that can metabolise a prodrug and release it in the cell of interest, or modify the drug without impacting activity to increase retention time within the cell
- Targeting of ligases, proteases or autophagy receptors that can selectively initiate protein degradation of the target in the cell of interest
- Opportunities to target tissue resident immune cells with a focus on macrophage and fibroblasts, including those resident in synovium, skin, and the GI tract
- Capability to differentially identify and target the same cell in different tissues

Diseases and Modalities of Interest

- Diseases in the areas of Rheumatology, Dermatology and GI inflammation are of particular interest (relevant research within other inflammatory diseases is also of interest)
- Preference is given to research focused on small molecule ligands, however all modalities are within scope

Developmental Stage

- Basic research to late preclinical development is within scope
- Research should have *in vitro* proof of principle and have evidence of lack of uptake in off-target cells
- Preference for research with additional *ex vivo* or *in vivo* evidence






Out of Scope

Non-selective technologies, i.e. non-targeted nanoparticles that rely on non-selective uptake.

Incentives for Academics

Johnson & Johnson Innovation is seeking a partner/collaborator with unique expertise or assets in the field of precision immunotherapy. The ideal scenario would involve starting collaborations with the teams behind the submitted opportunities.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: **26th April 2021 - 10:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk

